Filings

8 documents · 37 matches

1. AVIR Atea Pharmaceuticals, Inc. 10-Q 2026-08-12

   Item 1A. Risk Factors.

   tariffs enacted by the US federal government in 2025 have been subject to successful legal challenge leading to some tariffs
   4 matches in this document Show context Copy citation

2. AVIR Atea Pharmaceuticals, Inc. 10-Q 2026-11-09

   Item 1A. Risk Factors.

   tariffs enacted by the US federal government in 2025 have been subject to successful legal challenge leading to some tariffs
   5 matches in this document Show context Copy citation

3. AVIR Atea Pharmaceuticals, Inc. 10-K 2026-03-05

   Item 1A. Risk Factors.

   tariffs may be refunded, and the US federal government may attempt to impose new or similar tariffs under alternative statutory
   5 matches in this document Show context Copy citation

4. AVIR Atea Pharmaceuticals, Inc. 10-Q 2026-05-12

   Item 1A. Risk Factors.

   tariffs may be refunded, and the US federal government may attempt to impose new or similar tariffs under alternative statutory
   5 matches in this document Show context Copy citation

5. AVIR Atea Pharmaceuticals, Inc. 10-K 2021-03-30

   Item 1A. Risk Factors.

   tariff free trading of goods, it is nevertheless expected that the TCA will result in the creation of non-tariff
   2 matches in this document Show context Copy citation

6. AVIR Atea Pharmaceuticals, Inc. 10-Q 2025-11-12

   Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

   impacted if tariffs are imposed on pharmaceutical products or the materials, including regulatory starting materials, necessary to manufacture our product candidates;
   6 matches in this document Show context Copy citation

7. AVIR Atea Pharmaceuticals, Inc. 10-Q 2025-08-07

   Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

   impacted if tariffs are imposed on pharmaceutical products or the materials, including regulatory starting materials, necessary to manufacture our product candidates;
   5 matches in this document Show context Copy citation

8. AVIR Atea Pharmaceuticals, Inc. 10-Q 2025-05-12

   Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

   impacted if tariffs are imposed on pharmaceutical products or the materials, including regulatory starting materials, necessary to manufacture our product candidates;
   5 matches in this document Show context Copy citation